Biologic agents and liver toxicity: An added concern or therapeutic opportunity?

Nature Clinical Practice Rheumatology

Volumn 3, Issue 8, 2007, Pages 422-423

  Calabrese, Leonard H ^a   Zein, Nizar ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; BIOLOGICAL PRODUCT; CYTOKINE; ETANERCEPT; IMMUNOLOGIC AGENT; INFLIXIMAB; INTERFERON; INTERLEUKIN 6; METHOTREXATE; PLACEBO; RIBAVIRIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; CHRONIC HEPATITIS; CLINICAL TRIAL; CROHN DISEASE; CRYOGLOBULINEMIA; DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; HEPATITIS B; HEPATITIS C; HUMAN; INFECTIOUS COMPLICATION; LIVER FUNCTION; LIVER INJURY; LIVER TOXICITY; NONHUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; SPONDYLOARTHROPATHY; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULITIS; VIRUS LOAD;

BIOLOGICAL FACTORS; HEPATITIS C, CHRONIC; HUMANS; LIVER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547566340     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0537     Document Type: Review

References (11)

1. Desai SB and Furst DE (2006) Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 20: 757-790
2. Remicader® (Centocor, Inc. Horsham, PA) website [http://www.remicade.com]
3. Feletar M et al. (2004) Treatment of refractory psoriatic arthritis with infliximab: A 12 month observational study of 16 patients. Ann Rheum Dis 63: 156-161
4. Germano V et al. (2005) Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 64: 1519-1520
5. Maini RN et al. (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54: 2817-2829
6. Gao B (2005) Cytokines, STATs and liver disease. Cell Mol Immunol 2: 92-100
7. Calabrese LH et al. (2006) Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: Assessment and preventive strategies. Ann Rheum Dis 65: 983-989
8. Beyaert R and Fiers W (1998) Tumor necrosis factor and lymphotoxin. In Cytokines, 335-361 (Eds Mire-Sluis AR and Thorpe R) San Diego, CA: Academic Press
9. Zein NN, Etanercept Study Group (2005) Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: A phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 42: 315-322
10. Peterson JR et al. (2003) Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62: 1078-1082
11. Ferri C and Mascia MT (2006) Cryoglobulinemic vasculitis. Curr Opin Rheumatol 18: 54-63